Transforming orthopaedics and regenerative medicine through pioneering use of nanoclay gels stemming from world-class stem cell research

Renovos is an exciting opportunity for bioscience investors who share our vision of innovation in the regenerative medicine space for active living.

Our motivation is to unlock the full potential of regenerative medicine with our innovative Renovite® nanoclay gel technology platform, and help clinicians deliver more efficacious treatments for tissue repair without side-effects.

Growing market and need

$17bn

spinal fusion and foot and ankle markets by 2022

>3m

spinal fusion procedures worldwide every year

>$5bn

orthobiologics market by 2021, growing rapidly

Renovos is focusing on the orthobiologics and regenerative medicine markets, whose growth is driven by both an ageing population and more active younger demographics. The Renovite® platform will deliver products that are easier to use and more effective, and most importantly safer.

The anticipated commercial and health economic proposition for the first product, Renovite® BMP-2 gel (addressing c. $1bn market), as well as following biologics products based on the Renovite® platform, is clear:

the safe and rapid application of the biologic will reduce the incidence of failed procedures and associated revisions, allowing for an attractive price point for the product while taking significant costs out of the healthcare system

as a product injectable via a narrow gauge needle, it can further expand the addressable market by facilitating application of biologics in minimally invasive procedures

the decreased risk of side effects and ectopic bone formation should allow for access to biologics for higher risk patients, which further extends the economic impact to previously unserved patient pools.

Broad platform technology

knee-and-spine-centre

bone / cartilage

tooth-centre-small

dental

skin-centre

skin

Renovos is pioneering the use of synthetic nanoclay gels for medical use. The Renovite® nanoclay gel platform can be used to deliver, retain and safely release biologics for tissue regeneration in multiple applications, making step-change improvements in a wide range of current procedures. Our proprietary formulations:

are easy to handle

form a biodegradable gel scaffold after injection

can deliver ultra-low doses of biologics

retain the biologics and release only to cells growing into the nanoclay, for increased safety and efficacy.

Novel breakthrough technology but with a low technical risk and easy scale-up

Various nanoclays are already used as components in some drugs and cosmetics and carry low developmental risk. All of Renovos’ work is underpinned by decades of rigorous research by the same core team. Consequently, this has built up the skills and know-how of the team, facilitating technical success and rapid product development. Renovos’ core skills and IP are in formulation and development, and all the processes developed to date can be expanded and scaled without major technical challenges.

Get in touch

Please get in touch for more information on investment opportunities at investors@renovos.co.uk